Navigation Links
Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS**
Date:8/25/2009

one of Amplimmune's founders, Dr. Lieping Chen, at The Johns Hopkins University, we are pleased to form this collaboration with Fast Forward which will help accelerate AMP-110 into clinical testing."

The National Multiple Sclerosis Society funds research in a range of scientific areas including immune mechanisms, genetics, nerve regeneration and symptom managements. The agreement with Amplimmune is a part of the Society's Fast Forward initiative through which Fast Forward will partner with young innovative biotechnology and pharmaceutical companies to develop treatments, diagnostics, medical devices, and related technologies to treat, reverse and ultimately cure MS. Under the terms of the agreement, Fast Forward will provide Amplimmune with funds to support preclinical development of AMP-110. In consideration, Fast Forward will receive warrants to purchase shares of the company.

**NOTE TO EDITORS: Fast Forward's partnership with Amplimmune continues to expand its role in spurring MS drug development in the emerging biotech market and follows on its successful alliances with Apitope International to fund a proof of principle clinical trial for a peptide therapeutic vaccine and with Provid Pharmaceuticals to develop a novel compound intended to redirect abnormal immune response. It also builds on Fast Forward's $19 million collaborative partnership with EMD Serono to accelerate innovation and commercial development of MS therapies through a group of soon to be determined, mutually agreed upon seed-to-early stage projects. Emerging biotechnology companies face many challenges in the current economy, and Fast Forward is determined to deploy its resources to spearhead the continued development of promising MS therapies.

About Fast Forward, LLC
Fast Forward, LLC is a nonprofit organization established by the National Multiple Sclerosis Society in order to accelerate the development of treatments for MS. Fast Forward will accomplis
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4

Related biology technology :

1. Research Reinforces Economic, Environmental Benefits of Corn Cobs as Source for Cellulosic Ethanol
2. New Brain Fitness Survey Reinforces Importance of Brain Awareness Week
3. Bio-Tech Medical Software, Inc. Biometrics Joins Forces with the University of Central Florida to Fight Diversion and Help Combat Prescription Narcotic Drug Abuse
4. Oslo and Toulouse Cancer Clusters Join Forces to Drive European Cancer Research Forward
5. Osteotechs Plexur(R) Technology to Be Used in Craniofacial Reconstruction Program Funded by the Armed Forces Institute of Regenerative Medicine
6. DMetrix and the Armed Forces Radiobiology Research Institute Announce Cooperative Research and Development Agreement
7. Ketchum Joins Forces with Clinical Trial Recruitment Agency MMG
8. Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD)
9. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
10. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
11. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 
(Date:5/21/2015)... -- Prima Biomed Ltd. (NASDAQ: PBMD ) a globally ... leader in the development of immunotherapeutic products for the ... data from the Phase II CAN-003 ovarian cancer clinical ... meaningful improvement in Overall Survival ("OS") over standard of ... the group of second remission patients (n=20), the median ...
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 W. ... its manufacturing facility in Worms, Germany has received ... independent subsidiary of the International Pharmaceutical Excipient Council ... facilities that produce its SYLOID® FP brand of ... GMP certification, following the Curtis Bay, Maryland (USA) ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... Toronto Stock Exchange Symbol: LRILAVAL, QC, Feb. 9 /PRNewswire-FirstCall/ ... "Company") (TSX: LRI), a Canadian-based global non-clinical contract research ... Spalding as Chairman of its Board of Directors in ... wish to step down of the Board to focus ...
... and PARIS, February 9 Debiopharm,Group (Debiopharm), ... serious medical conditions and particularly oncology, and,Pharmaleads ... early development,company, today announced the signature of ... and commercialisation of a small molecule,called Debio ...
... 3SBio Inc.,(Nasdaq: SSRX ), a leading ... biopharmaceutical products primarily,in China, today announced that it ... effective February 1, 2009. Since joining 3SBio in ... financial advisor for the company, providing advice,on the ...
Cached Biology Technology:LAB Research announces changes to its Board of Directors 2Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions 2Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions 33SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer 2
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
(Date:4/27/2015)... Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... pre-order customers the first week of May, 2015 and ... of May. Gino Pereira , ... for the company as Wocket® enters the consumer market. ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... Covalys Biosciences AG today announced a collaboration to ... generate SNAP-tag fusion proteins based on Gene Bridges' ... does not require restriction enzymes and allows the ... (bacterial artificial chromosomes) with single-nucleotide precision. SNAP-tag is ...
... Like humans, other animals are faced with everyday obstacles ... and motor skills to deal with them. Navigating these ... other vertebrates, but in new work, researchers have employed ... structure of goal-oriented motor programs in the fruit fly ...
... help stem the global HIV epidemic is to give ... drug tenofovir) before they have high risk sex in ... an approach called "pre-exposure prophylaxis" (PREP). But activist groups, ... least two important clinical trials of tenofovir as PREP ...
Cached Biology News:Gene Bridges And Covalys To Develop Restriction-Enzyme-Free SNAP-tag Gene Fusion Kits 2Gap-climbing fruit flies reveal components of goal-driven behaviors 2Why were the HIV prevention trials in commercial sex workers abandoned? 2
96 Well Plate EB, RE bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes. Guaranteed coefficient of variation (CVs)....
The Holten mini vertical flow workbench provides a particle-free environment for sample protection against airborne contaminants....
...
Medium bottle for hybridization 250 x 35mm...
Biology Products: